High ORR and low CRS rate with Linvoseltamab for R/R Multiple Myeloma

Recently Jeffrey Zonder shared a post on X about a recent paper by Naresh Bumma et al. titled “Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma” published in JCO. .

Quoting Jeffrey Zonder’s comment:

“Know what I love most about this paper?

Not the high ORR and low CRS rate with Linvoseltamab for R/R Multiple Myeloma (though these are impressive).

It’s that one of our former Karmanos Cancer Institute fellows Dr. Naresh Bumma is the lead author. Congrats!”

Source: Jeffrey Zonder/X

Jeffrey Zonder is a Hematologist at the Barbara Ann Karmanos Cancer Institute (KCI), with over 20 years of experience as a clinical researcher specializing in clonal plasma cell disorders, particularly multiple myeloma and amyloidosis. He established and currently leads the Multiple Myeloma and Amyloidosis Multidisciplinary Team and Research Program at KCI in Detroit, Michigan.

Additionally, he serves as Co-Director of Molecular Therapeutics (Hematology) at KCI. An avid hiker, backpacker, and runner, he has participated in fundraising distance running events, including the New York City Marathon, and treks to Machu Picchu, Patagonia, Everest Base Camp, and Kilimanjaro in 2023, all supporting the Multiple Myeloma Research Foundation.

Naresh Bumma is a hematologist specializing in the diagnosis and treatment of plasma cell disorders, including multiple myeloma and amyloidosis, at the Ohio State University Comprehensive Cancer Center – James (OSUCCC – James). His research focuses on harnessing the immune system to treat and cure cancer, with an emphasis on immunotherapy for multiple myeloma and amyloidosis. As a clinical investigator, his work has gained national and international recognition, and he has received the ASH Abstract Achievement Award multiple times.